Dosage ; see below
Combinations ; - see below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Cardimax | USV | Surgipharm Ltd | 20mg | 30 | Tablet | per tablet | KES 179.00 |
| Dinemic | Maple Pharmaceuticals Pvt. Ltd | Njimia Pharmaceuticals Ltd. | 20mg | 30 | Tablet | per tablet | KES 800 |
| Trimetazidine More info | |
|---|---|
| Mode Of Action | 3-KAT inhibitors (like trimetazidine), are metabolic anti-ischaemic agents that provide cardioprotection to coronary patients. They also act on sensory tissues. By preserving the energy metabolism in cells exposed to hypoxia or ischaemia, they prevent a decrease in intracellular ATP levels, thereby ensuring the proper functioning of ionic pumps and transmembrane sodum-potassium flow whilst maintaining cellular homeostasis. |
| Drug Indication | Long term treatment of Angina pectoris; adjuvant symptomatic treatment of vertigo and tinnitus; adjuvant treatment of visual disorders of circulatory origin. |
| Contra-Indications | Hypersensitivity to trimetazidine; pregnancy; breastfeeding. |
| Side Effects | Nausea; vomiting; headache. |
| Dosage | Dose for MR 35mg tablets: One tablet at meal times in the morning and evening. Dose for 20mg tablets: 40-60mg orally daily in divided doses. |
| Drug Category | DRUGS ACTI NG ON THE CARDIO-VASCULAR SYSTEM |
| Drug Sub-Category | Metabolic anti-ischemic agents |